What is HC Wainwright’s Estimate for CADL FY2024 Earnings?

Candel Therapeutics, Inc. (NASDAQ:CADL) – Investment analysts at HC Wainwright increased their FY2024 EPS estimates for shares of Candel Therapeutics in a report issued on Wednesday, December 18th. HC Wainwright analyst V. Bernardino now anticipates that the company will earn ($1.59) per share for the year, up from their previous forecast of ($1.65). HC Wainwright currently has a “Buy” rating and a $19.00 target price on the stock. The consensus estimate for Candel Therapeutics’ current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Candel Therapeutics’ Q4 2024 earnings at ($0.27) EPS and FY2025 earnings at ($1.35) EPS.

Candel Therapeutics Stock Up 52.5 %

Shares of CADL opened at $9.96 on Friday. Candel Therapeutics has a fifty-two week low of $1.02 and a fifty-two week high of $14.60. The firm has a market cap of $323.46 million, a PE ratio of -5.76 and a beta of -0.95. The company has a quick ratio of 1.18, a current ratio of 1.18 and a debt-to-equity ratio of 1.66. The company’s fifty day moving average is $5.41 and its two-hundred day moving average is $6.05.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the business. Point72 DIFC Ltd acquired a new stake in Candel Therapeutics in the second quarter valued at $31,000. FMR LLC acquired a new stake in shares of Candel Therapeutics during the third quarter worth $46,000. MetLife Investment Management LLC acquired a new stake in shares of Candel Therapeutics during the third quarter worth $87,000. Atom Investors LP bought a new position in shares of Candel Therapeutics in the 3rd quarter worth about $103,000. Finally, Rhumbline Advisers acquired a new position in shares of Candel Therapeutics in the 2nd quarter valued at about $143,000. Institutional investors and hedge funds own 13.93% of the company’s stock.

Insiders Place Their Bets

In other news, insider William Garrett Nichols sold 13,935 shares of Candel Therapeutics stock in a transaction that occurred on Friday, November 29th. The shares were sold at an average price of $4.56, for a total transaction of $63,543.60. Following the sale, the insider now owns 100,547 shares in the company, valued at $458,494.32. This trade represents a 12.17 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Estuardo Aguilar-Cordova sold 15,000 shares of Candel Therapeutics stock in a transaction on Monday, October 14th. The stock was sold at an average price of $6.02, for a total transaction of $90,300.00. Following the sale, the insider now directly owns 929,873 shares in the company, valued at $5,597,835.46. This trade represents a 1.59 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 66,127 shares of company stock worth $349,911 over the last three months. 41.60% of the stock is owned by insiders.

Candel Therapeutics Company Profile

Candel Therapeutics, Inc, a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase II clinical trials for the treatment of pancreatic cancer; Phase III clinical trials for the treatment of prostate cancer; and Phase II clinical trials for the treatment of lung cancer, as well as has completed Phase Ib/II clinical trials for the treatment of high-grade glioma.